Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
The top names.
Perrigo leading the charge.
Here's what you need to know now for Wed., Aug. 9.
All eyes are on Pfizer in the months ahead.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.